MX9304435A - PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES. - Google Patents

PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES.

Info

Publication number
MX9304435A
MX9304435A MX9304435A MX9304435A MX9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A
Authority
MX
Mexico
Prior art keywords
treatment
prophylaxis
composition
obesity
diabetes
Prior art date
Application number
MX9304435A
Other languages
Spanish (es)
Inventor
Barbara Anne Spicer
Kathryn Gay Ellis
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9304435A publication Critical patent/MX9304435A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un método para el tratamiento y/o la profilaxis de la obesidad o para el tratamiento de la diabetes del Tipo II en mamíferos, tales como humanos, que comprende administrar al mamífero en necesidad de tal tratamiento y/o profilaxis, una cantidad efectiva y/o profiláctica, no tóxica del Compuesto 1 (1,3-di-cicloprometil-8-amino-xantina).A method for the treatment and / or prophylaxis of obesity or for the treatment of Type II diabetes in mammals, such as humans, is disclosed which comprises administering to the mammal in need of such treatment and / or prophylaxis, an effective amount and / or prophylactic, non-toxic of Compound 1 (1,3-di-cyclopromethyl-8-amino-xanthine).

MX9304435A 1992-07-23 1993-07-22 PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES. MX9304435A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment

Publications (1)

Publication Number Publication Date
MX9304435A true MX9304435A (en) 1994-04-29

Family

ID=10719151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304435A MX9304435A (en) 1992-07-23 1993-07-22 PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES.

Country Status (9)

Country Link
EP (1) EP0651642A1 (en)
JP (1) JPH07509456A (en)
CN (1) CN1043610C (en)
AU (1) AU4714393A (en)
GB (1) GB9215633D0 (en)
MX (1) MX9304435A (en)
TW (1) TW258663B (en)
WO (1) WO1994002150A1 (en)
ZA (1) ZA935339B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783408A (en) * 1995-06-07 1998-07-21 Hamilton; Bradford S. Method for screening potential anti-obesity agents
PT1757606E (en) * 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Xanthinderivatives for use as medical agents and the preparation thereof
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2003004496A1 (en) * 2001-07-03 2003-01-16 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
WO2003024965A2 (en) * 2001-09-19 2003-03-27 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (en) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
MXPA06002521A (en) 2003-09-05 2006-06-20 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (en) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazoles and triazoles, their preparation and use as medicines
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
EP1874308A1 (en) 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
CN102149407A (en) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (en) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Saline forms of organic compounds
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
CN102753161A (en) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
ES2713566T3 (en) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivative of substituted dinamic quinazoline, its preparation and its use in pharmaceutical compositions for the treatment of type I and II diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
JP2019517542A (en) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of linagliptin and metformin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds

Also Published As

Publication number Publication date
AU4714393A (en) 1994-02-14
TW258663B (en) 1995-10-01
WO1994002150A1 (en) 1994-02-03
EP0651642A1 (en) 1995-05-10
CN1043610C (en) 1999-06-16
GB9215633D0 (en) 1992-09-09
CN1114880A (en) 1996-01-17
ZA935339B (en) 1995-01-18
JPH07509456A (en) 1995-10-19

Similar Documents

Publication Publication Date Title
MX9304435A (en) PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF OBESITY OR FOR THE TREATMENT OF TYPE II DIABETES.
DE3587434D1 (en) ANTIVIRAL PHARMACEUTICAL COMPOSITIONS AND THEIR USE.
KR890004709A (en) Azithromycin and its derivatives as antiprotozoal agents
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
KR960703009A (en) Use of modafinil for the treatment of centrally-derived sleep apnea and dyspnea
ZA921538B (en) Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same
ES2172654T3 (en) USE OF NSAID FOR THE TREATMENT OF SCALE CARCINOMAS OF THE ORAL OR OROPHARING CAVITY.
CA2002859A1 (en) Method of treating epithelial disorders
PE13197A1 (en) VENLAFAXINE IN THE TREATMENT OF HYPOTHALAMIC AMENORRHEA IN NON-DEPRESSED WOMEN
MY106067A (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors.
NO940266L (en) Internal radiation damage
AR247984A1 (en) Anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent
MX9301387A (en) METHOD AND COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS.
SE8904354D0 (en) A PHARMACEUTICAL COMPOSITION
ES2092868T3 (en) USE OF DERIVATIVES OF 4-THYORRESORCINE IN A COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF DEPIGMENTING ACTION.
BR0210744A (en) Synergistically Pharmaceutical Combination for the Prevention or Treatment of Diabetes
DE3166111D1 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
CO4130200A1 (en) HELPFUL HIV PROTEASE INHIBITORS IN AIDS TREATMENT
MX9400040A (en) COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS.
MX9302985A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF ANXIETY.
ES2088877T3 (en) 3-PIRROLIDINOL PREPARATION PROCEDURE.
MD960168A (en) Method for treatment of viral infections and compounds therefor
MX9300205A (en) DISUBSTITUTED POLYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
MX9300203A (en) DISUBSTITUTED POLYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
BR9810292A (en) Diabetes treatment with thiazolidinedione, insulin secretagogue and alpha-glucosidase inhibitor